<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_prostate" title="Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones" shortTitle="prostate" author="Sergey  A. Dyshlovoy, Dmitry  N. Pelageev, Jessica Hauschild, Ksenia  L. Borisova, Moritz Kaune, Christoph Krisp, Simone Venz, Yurii  E. Sabutskii, Ekaterina  A. Khmelevskaya, Tobias Busenbender, Vladimir  A. Denisenko, Natalia  D. Pokhilo, Lyubov  N. Atopkina, Markus Graefen, Hartmut Schlüter, Valentin  A. Stonik, Carsten Bokemeyer, Victor  Ph. Anufriev, Gunhild von Amsberg" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2072-6694/11/11/1690/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
3.	LS	3.
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
Increased	VBN	increase
selectivity	NN	selectivity
and	CC	and
efficacy	NN	efficacy
can	MD	can
be	VB	be
achieved	VBN	achieve
by	IN	by
linking	VBG	link
cytotoxic	JJ	cytotoxic
anticancer	NN	anticancer
drugs	NNS	drug
to	IN	to
specific	JJ	specific
target/carrier	NN	target/carrier
molecules	NNS	molecule
.	.	.
</s>
<s type="decl">
Successful	JJ	successful
examples	NNS	example
of	IN	of
this	DT	this
treatment	NN	treatment
strategy	NN	strategy
are	VBP	be
antibody-drug	JJ	antibody-drug
conjugates	NNS	conjugate
,	,	,
which	WDT	which
target	VBP	target
cancer	NN	cancer
cells	NNS	cell
due	JJ	due
to	IN	to
increased	VBN	increase
expression	NN	expression
of	IN	of
specific	JJ	specific
proteins	NNS	protein
,	,	,
and	CC	and
folate	NN	folate
conjugates	NNS	conjugate
,	,	,
which	WDT	which
utilize	VBP	utilize
a	DT	a
commonly	RB	commonly
high	JJ	high
expression	NN	expression
of	IN	of
the	DT	the
folate	NN	folate
receptor	NN	receptor
(	-LRB-	(
FR	NN	FR
)	-RRB-	)
on	IN	on
the	DT	the
surface	NN	surface
of	IN	of
different	JJ	different
human	JJ	human
cancer	NN	cancer
cells	NNS	cell
.	.	.
</s>
</p>
<p>
<s type="decl">
Warburg	NNP	Warburg
effect	NN	effect
targeting	VBG	target
is	VBZ	be
another	DT	another
promising	JJ	promising
strategy	NN	strategy
for	IN	for
the	DT	the
design	NN	design
and	CC	and
synthesis	NN	synthesis
of	IN	of
new	JJ	new
cytotoxic	JJ	cytotoxic
anticancer	NN	anticancer
drugs	NNS	drug
.	.	.
</s>
<s type="sub">
Here	RB	here
,	,	,
the	DT	the
conjugation	NN	conjugation
of	IN	of
sugar	NN	sugar
residues	NNS	residue
to	IN	to
cytotoxic	JJ	cytotoxic
drugs	NNS	drug
shall	MD	shall
increase	VB	increase
selectivity	NN	selectivity
to	IN	to
cancerous	JJ	cancerous
tissues	NNS	tissue
and	CC	and
reduce	VB	reduce
side	NN	side
effects	NNS	effect
in	IN	in
patients	NNS	patient
due	IN	due
to	IN	to
a	DT	a
higher	JJR	high
sugar	NN	sugar
uptake	NN	uptake
by	IN	by
the	DT	the
cancer	NN	cancer
cells	NNS	cell
.	.	.
</s>
<s type="decl">
To	IN	to
date	NN	date
one	CD	one
sugar-conjugated	JJ	sugar-conjugated
molecule	NN	molecule
glufosfamide	NN	glufosfamide
is	VBZ	be
in	IN	in
clinical	JJ	clinical
development	NN	development
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
lung	NN	lung
,	,	,
ovary	NN	ovary
,	,	,
pancreatic	JJ	pancreatic
,	,	,
brain	NN	brain
and	CC	and
CNS	NNP	CNS
cancer	NN	cancer
as	RB	as
well	RB	well
as	IN	as
soft	JJ	soft
tissue	NN	tissue
sarcoma	NNS	sarcoma
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
different	JJ	different
sugar-conjugated	JJ	sugar-conjugated
molecules	NNS	molecule
are	VBP	be
currently	RB	currently
evaluated	VBN	evaluate
preclinically	RB	preclinically
.	.	.
</s>
<s type="decl">
In	IN	in
prostate	NN	prostate
cancer	NN	cancer
Warburg	NNP	Warburg
effect	NN	effect
was	VBD	be
observed	VBN	observe
specifically	RB	specifically
in	IN	in
metastatic	JJ	metastatic
tumors	NNS	tumor
which	WDT	which
makes	VBZ	make
glucose-derived	JJ	glucose-derived
chemotherapeutics	NNS	chemotherapeutics
promising	JJ	promising
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
metastatic	JJ	metastatic
CRPC	NNP	CRPC
.	.	.
</s>
<s type="decl">
In	IN	in
our	PRP$	our
research	NN	research
,	,	,
we	PRP	we
found	VBD	find
the	DT	the
derivatives	NNS	derivative
of	IN	of
natural	JJ	natural
1,4-naphtoquinone	NN	1,4-naphtoquinone
compounds	NNS	compound
to	TO	to
be	VB	be
active	JJ	active
in	IN	in
drug-resistant	JJ	drug-resistant
prostate	NN	prostate
cancer	NN	cancer
cells	NNS	cell
.	.	.
</s>
<s type="decl">
Preliminary	JJ	Preliminary
data	NNS	datum
,	,	,
however	RB	however
,	,	,
have	VBP	have
shown	VBN	show
that	IN	that
these	DT	this
substances	NNS	substance
are	VBP	be
also	RB	also
rather	RB	rather
cytotoxic	JJ	cytotoxic
for	IN	for
non-cancerous	JJ	non-cancerous
cells	NNS	cell
,	,	,
suggesting	VBG	suggest
undesired	JJ	undesired
side	NN	side
effects	NNS	effect
<hi rend="italic">
in	IN	in
vivo	NN	vivo
</hi>
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
we	PRP	we
utilized	VBD	utilize
the	DT	the
Warburg	NNP	Warburg
effect	NN	effect
in	IN	in
order	NN	order
to	TO	to
increase	VB	increase
the	DT	the
selectivity	NN	selectivity
of	IN	of
the	DT	the
compounds	NNS	compound
towards	IN	towards
tumor	NN	tumor
cells	NNS	cell
.	.	.
</s>
<s type="decl">
We	PRP	we
synthesized	VBD	synthesize
hybrid	JJ	hybrid
molecules	NNS	molecule
,	,	,
which	WDT	which
contain	VBP	contain
selected	VBN	select
natural	JJ	natural
1,4-naphtoquinone	NN	1,4-naphtoquinone
moieties	NNS	moiety
conjugated	VBN	conjugate
with	IN	with
glucose	NN	glucose
residues	NNS	residue
via	IN	via
non-glycoside	JJ	non-glycoside
bond	NN	bond
at	IN	at
C6	NNP	C6
position	NN	position
.	.	.
</s>
<s type="decl">
The	DT	the
non-glycoside	JJ	non-glycoside
nature	NN	nature
of	IN	of
the	DT	the
conjugates	NNS	conjugate
was	VBD	be
chosen	VBN	choose
in	IN	in
order	NN	order
to	TO	to
provide	VB	provide
the	DT	the
highest	JJS	high
affinity	NN	affinity
to	IN	to
glucose	NN	glucose
transporters	NNS	transporter
located	VBN	locate
in	IN	in
the	DT	the
cellular	JJ	cellular
membrane	NN	membrane
.	.	.
</s>
<s type="decl">
It	PRP	it
is	VBZ	be
known	VBN	know
that	IN	that
the	DT	the
presence	NN	presence
of	IN	of
free	JJ	free
unsubstituted	JJ	unsubstituted
glycoside	NN	glycoside
hydroxyl	NN	hydroxyl
(	-LRB-	(
at	IN	at
C1	NN	C1
position	NN	position
)	-RRB-	)
is	VBZ	be
important	JJ	important
for	IN	for
the	DT	the
stabilization	NN	stabilization
of	IN	of
hydrogen	NN	hydrogen
bonding	NN	bonding
interactions	NNS	interaction
with	IN	with
GLUT-1	NN	GLUT-1
and	CC	and
therefore	RB	therefore
is	VBZ	be
required	VBN	require
for	IN	for
the	DT	the
successful	JJ	successful
cellular	JJ	cellular
uptake	NN	uptake
of	IN	of
the	DT	the
sugar-conjugated	JJ	sugar-conjugated
molecules	NNS	molecule
.	.	.
</s>
<s type="decl">
In	IN	in
contrast	NN	contrast
,	,	,
the	DT	the
hydroxyl	NN	hydroxyl
at	IN	at
C6	NNP	C6
position	NN	position
of	IN	of
glucose	NN	glucose
molecule	NN	molecule
is	VBZ	be
not	RB	not
relevant	JJ	relevant
for	IN	for
the	DT	the
hydrogen	NN	hydrogen
bond	NN	bond
interactions	NNS	interaction
and	CC	and
therefore	RB	therefore
it	PRP	it
’s	VBZ	be
substitution	NN	substitution
may	MD	may
be	VB	be
more	RBR	more
tolerable	JJ	tolerable
.	.	.
</s>
<s type="decl">
In	IN	in
fact	NN	fact
,	,	,
the	DT	the
affinity	NN	affinity
of	IN	of
glucose	NN	glucose
with	IN	with
substituted	VBN	substitute
C6-OH	NNP	C6-OH
to	IN	to
GLUT-1	NNP	GLUT-1
was	VBD	be
reported	VBN	report
to	TO	to
be	VB	be
almost	RB	almost
equal	JJ	equal
to	IN	to
its	PRP$	its
unsubstituted	JJ	unsubstituted
analogues	NNS	analogue
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
instead	RB	instead
of	IN	of
a	DT	a
conventional	JJ	conventional
glycosylation	NN	glycosylation
reaction	NN	reaction
(	-LRB-	(
results	NNS	result
in	IN	in
C1-substituted	JJ	C1-substituted
glucose	NN	glucose
)	-RRB-	)
we	PRP	we
applied	VBD	apply
a	DT	a
new	JJ	new
reaction	NN	reaction
of	IN	of
alkylation	NN	alkylation
of	IN	of
2-hydroxy-1,4-naphthoquinones	NN	2-hydroxy-1inap1oquinones
with	IN	with
6-deoxy-6-iodo-1,2:3,5-di-O-	NNP	6-deoxy-6-iodo-1,2:3,5-di-O-
isopropylidene-α-D-glucofuranose	NN	isopropylidene-α-D-glucofuranose
(	-LRB-	(
results	NNS	result
in	IN	in
a	DT	a
C6-substituted	JJ	C6-substituted
glucose	NN	glucose
)	-RRB-	)
.	.	.
</s>
<s type="decl">
This	DT	this
reaction	NN	reaction
was	VBD	be
more	RBR	more
efficient	JJ	efficient
in	IN	in
comparison	NN	comparison
with	IN	with
transesterification	NN	transesterification
reaction	NN	reaction
of	IN	of
2-methoxy-1,4-naphthoquinones	NN	2-methoxy-1inap1oquinones
,	,	,
which	WDT	which
was	VBD	be
recently	RB	recently
discovered	VBN	discover
by	IN	by
us	PRP	we
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
we	PRP	we
synthesized	VBD	synthesize
a	DT	a
series	NN	series
of	IN	of
6-(1,4-naphtoquinonyl)-D-glucose	NN	6-(1,4-naphtoquinonyl)-D-glucose
conjugates	NNS	conjugate
containing	VBG	contain
diprotected	JJ	diprotected
,	,	,
monoprotected	JJ	monoprotected
,	,	,
or	CC	or
unprotected	JJ	unprotected
glucose	NN	glucose
residues	NNS	residue
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
line	NN	line
with	IN	with
our	PRP$	our
hypotheses	NNS	hypothesis
the	DT	the
glucose-conjugated	JJ	glucose-conjugated
compounds	NNS	compound
revealed	VBD	reveal
higher	JJR	high
selectivity	NN	selectivity
towards	IN	towards
five	CD	5
human	JJ	human
prostate	NN	prostate
cancer	NN	cancer
cell	NN	cell
lines	NNS	line
compared	VBN	compare
with	IN	with
five	CD	5
non-cancerous	JJ	non-cancerous
lines	NNS	line
.	.	.
</s>
<s type="decl">
The	DT	the
successful	JJ	successful
targeting	NN	targeting
of	IN	of
the	DT	the
Warburg	NNP	Warburg
effect	NN	effect
by	IN	by
the	DT	the
newly	RB	newly
synthesized	VBN	synthesize
glucose	NN	glucose
derivatives	NNS	derivative
is	VBZ	be
strongly	RB	strongly
suggested	VBN	suggest
by	IN	by
the	DT	the
following	VBG	follow
findings	NNS	finding
:	:	:
(	:	(
a	CD	a
)	-RRB-	)
correlation	NN	correlation
of	IN	of
cytotoxicity	NN	cytotoxicity
and	CC	and
selectivity	NN	selectivity
of	IN	of
the	DT	the
synthesized	VBN	synthesize
conjugates	NNS	conjugate
with	IN	with
higher	JJR	high
expression	NN	expression
of	IN	of
GLUT-1	NNP	GLUT-1
in	IN	in
human	JJ	human
prostate	NN	prostate
cancer	NN	cancer
cells	NNS	cell
;	:	;
(	-LRB-	(
b	CD	b
)	-RRB-	)
inhibition	NN	inhibition
of	IN	of
cytotoxicity	NN	cytotoxicity
of	IN	of
the	DT	the
conjugates	NNS	conjugate
by	IN	by
addition	NN	addition
of	IN	of
glucose	NN	glucose
to	IN	to
the	DT	the
media	NNS	media
;	:	;
c	NN	c
)	-RRB-	)
ability	NN	ability
of	IN	of
the	DT	the
compounds	NNS	compound
to	TO	to
inhibit	VB	inhibit
a	DT	a
glucose	NN	glucose
uptake	NN	uptake
by	IN	by
cancer	NN	cancer
cells	NNS	cell
.	.	.
</s>
<s type="decl">
In	IN	in
general	JJ	general
,	,	,
the	DT	the
binding	NN	binding
of	IN	of
the	DT	the
quinone	NN	quinone
core	NN	core
with	IN	with
the	DT	the
glucose	NN	glucose
moiety	NN	moiety
lead	VBP	lead
to	IN	to
an	DT	a
increased	VBN	increase
water	NN	water
solubility	NN	solubility
and	CC	and
selectivity	NN	selectivity
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
at	IN	at
the	DT	the
same	JJ	same
time	NN	time
it	PRP	it
resulted	VBD	result
in	IN	in
an	DT	a
absolute	JJ	absolute
cytotoxicity	NN	cytotoxicity
decrease	NN	decrease
when	WRB	when
compared	VBN	compare
to	IN	to
methoxy	NN	methoxy
derivatives	NNS	derivative
,	,	,
most	RBS	most
probably	RB	probably
due	JJ	due
to	IN	to
the	DT	the
increased	VBN	increase
polarity	NN	polarity
of	IN	of
the	DT	the
molecule	NN	molecule
.	.	.
</s>
<s type="sub">
It	PRP	it
should	MD	should
also	RB	also
be	VB	be
noted	VBN	note
that	IN	that
normal	JJ	normal
prostate	NN	prostate
cells	NNS	cell
are	VBP	be
known	VBN	know
to	TO	to
have	VB	have
an	DT	a
active	JJ	active
glycolysis	NN	glycolysis
and	CC	and
also	RB	also
consume	VBP	consume
significant	JJ	significant
amount	NN	amount
of	IN	of
glucose	NN	glucose
(	-LRB-	(
reviewed	VBN	review
in	IN	in
)	-RRB-	)
.	.	.
</s>
<s type="sub">
Thus	RB	thus
,	,	,
these	DT	this
cells	NNS	cell
may	MD	may
also	RB	also
be	VB	be
affected	VBN	affect
by	IN	by
the	DT	the
Warburg	NNP	Warburg
effect	NN	effect
targeting	VBG	target
therapeutics	NNS	therapeutics
in	IN	in
vivo	NN	vivo
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
frequently	RB	frequently
patients	NNS	patient
with	IN	with
advanced	JJ	advanced
prostate	NN	prostate
cancer	NN	cancer
have	VBP	have
had	VBN	have
local	JJ	local
treatment	NN	treatment
for	IN	for
their	PRP$	their
primary	JJ	primary
tumors	NNS	tumor
leaving	VBG	leave
no	DT	no
vital	JJ	vital
tissue	NN	tissue
behind	RB	behind
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
patients	NNS	patient
cytoreduction	NN	cytoreduction
of	IN	of
the	DT	the
remaining	VBG	remain
prostate	NN	prostate
tissue	NN	tissue
maybe	RB	maybe
a	DT	a
pleasant	JJ	pleasant
side	NN	side
effect	NN	effect
in	IN	in
order	NN	order
to	TO	to
avoid	VB	avoid
local	JJ	local
complications	NNS	complication
.	.	.
</s>
</p>
</text>